717 ORAL Gemcitabine (GEM) plus capecitabine (CAP) versus GEM alone in locally advanced or metastatic pancreatic cancer. aspects of quality of life in a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)

首页> 外文期刊>European Journal of Cancer Supplements >717 ORAL Gemcitabine (GEM) plus capecitabine (CAP) versus GEM alone in locally advanced or metastatic pancreatic cancer. aspects of quality of life in a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)

【24h】

717 ORAL Gemcitabine (GEM) plus capecitabine (CAP) versus GEM alone in locally advanced or metastatic pancreatic cancer. aspects of quality of life in a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)

机译：717在局部晚期或转移性胰腺癌中，口服吉西他滨（GEM）加卡培他滨（CAP）与单独的GEM对比。瑞士临床癌症研究小组（SAKK）和中欧合作肿瘤学小组（CECOG）进行的随机III期研究中的生活质量方面

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. [J] . Bernhard J, Dietrich D, Scheithauer W, Journal of Clinical Oncology . 2008,第22期

机译：接受吉西他滨联合卡培他滨与单用吉西他滨的晚期胰腺癌患者的临床获益和生活质量：一项随机的多中心III期临床试验-SAKK 44 / 00-CECOG / PAN.1.3.001。
2. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. [J] . Herrmann R, Bodoky G, Ruhstaller T, Journal of Clinical Oncology . 2007,第16期

机译：吉西他滨加卡培他滨与单用吉西他滨治疗晚期胰腺癌的比较：瑞士临床癌症研究组和中欧合作肿瘤学组的一项随机，多中心，III期试验。
3. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. [J] . Boeck S, Hoehler T, Seipelt G, Annals of oncology: official journal of the European Society for Medical Oncology . 2008,第2期

机译：卡培他滨加奥沙利铂（CapOx）与卡培他滨加吉西他滨（CapGem）与吉西他滨加奥沙利铂（mGemOx）：一项多中心随机II期晚期胰腺癌试验的最终结果。
4. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1 S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study [O] . Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, 2017

机译：吉西他滨加S-1S-1和吉西他滨单独用于局部晚期或转移性胰腺癌的随机III期研究中与健康相关的生活质量：GEST研究
5. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study [O] . Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, 2017

机译：与单独的吉西他滨加S-1，S-1单独和吉西他滨的随机相关的生命与单独用于局部晚期或转移性胰腺癌的卫生相关的生命质量研究：GEST研究

717 ORAL Gemcitabine (GEM) plus capecitabine (CAP) versus GEM alone in locally advanced or metastatic pancreatic cancer. aspects of quality of life in a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)

著录项

相似文献

相关主题

期刊订阅